Federico Gardini
Corporate Officer/Principal bei Bio3 Research SRL
Aktive Positionen von Federico Gardini
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - | - |
Karriereverlauf von Federico Gardini
Ehemalige bekannte Positionen von Federico Gardini
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bio3 Research, Inc. | Geschäftsführer | - | - |
Ausbildung von Federico Gardini
University of Bocconi | Undergraduate Degree |
Statistik
International
Italien | 3 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Health Technology |
Bio3 Research, Inc. |
- Börse
- Insiders
- Federico Gardini
- Erfahrung